This series of Reviews on cell death explores the creation of new therapies for correcting excessive or deficient cell death in human disease. Signal transduction pathways controlling cell death and the molecular core machinery responsible for cellular self-destruction have been elucidated with unprecedented celerity during the last decade, leading to the design of novel strategies for blocking pathological cell loss or for killing unwanted cells. Thus, an increasing number of compounds targeting a diverse range of apoptosis-related molecules are being explored at the preclinical and clinical levels. Beyond the agents that are already FDA approved, a range of molecules targeting apoptosis-regulatory transcription factors, regulators of mitochondrial membrane permeabilization, and inhibitors or activators of cell death-related proteases are under close scrutiny for drug development.
Introduction
Apoptosis was originally defined based on morphological features seen as the cell dies: nuclear condensation, nuclear fragmentation, membrane blebbing, cellular fragmentation into membrane-bound bodies, phagocytosis of the dying cell, and lack of an ensuing inflammatory response (1) . The final outcome - apoptosis - is generally the result of the activation of a subset of caspase proteases, in particular caspase-3, -6, and -7 (2). These are the "executioner" caspases, and they mediate their effects by cleavage of specific substrates in the cell. The executioner caspases, and, indeed, all of the core components of the apoptosis machinery, often preexist in healthy cells in inactive forms. Activation of the executioner caspase-3 and -7 by initiator caspase-8, -9, and -10 defines the best-understood apoptotic pathways, and we focus on these: the death receptor (extrinsic) pathway, and the mitochondrial (intrinsic) pathway.
In the extrinsic pathway, ligation of death receptors (a subset of the TNF receptor [TNFR] family, including TNFR1, CD95, TNFrelated apoptosis-inducing ligad receptor-1 and -2 [TRAIL-R1 and -R2], and probably DR3/TRAMP) causes recruitment and oligomerization of the adapter molecule FADD within the death-inducing signaling complex (DISC). The oligomerized FADD binds initiator caspase-8 and -10, causing their dimerization and activation (3) .
Most cell death in vertebrates proceeds via the mitochondrial pathway of apoptosis ( Figure 1 ) (4) . Here, the executioner caspases are cleaved and activated by the initiator caspase-9. Like other initiator caspases, caspase-9 can only be activated by dimerization on the adapter molecule Apaf-1. Apaf-1 preexists in the cytosol as a monomer, and its activation depends on the presence of holocytochrome c. Upon binding of cytochrome c to Apaf-1, dATP gains access to a nucleotide-binding site in Apaf-1, inducing a conformational change in the adapter molecule (5) . Apaf-1 then oligomerizes into an "apoptosome" that recruits and activates caspase-9 (6) . The release of holocytochrome, which is normally present only in the mitochondrial intermembrane space, is rate-limiting for the generation of the apoptosome. Hence, mitochondrial outer membrane permeabilization (MOMP) is the critical event responsible for caspase activation in the intrinsic pathway. However, MOMP, which represents the "point of no return" of cell death, can even commit a cell to die when caspases are not activated. This "caspase-independent death" (7, 8) can occur due to irreversible loss of mitochondrial function and mitochondrial release of caspase-independent death effectors such as apoptosisinducing factor (AIF) (9), endonuclease G (10), and others (7, 8) .
In ischemic injury and other clinical conditions, MOMP can occur as a consequence of the mitochondrial permeability transition (MPT). Channels in the inner mitochondrial membrane open to allow movement of solutes and ions, resulting in a loss of inner membrane function and swelling of the matrix. This can lead to matrix remodeling, perhaps freeing proteins of the intermembrane space for release, and can lead to outer membrane rupture. The opening of the MPT involves the adenosine nuclear transporter (ANT) in the inner mitochondrial membrane, although this is not absolutely required for MPT (11) , and the voltage-dependent anion channels (VDACs) in the outer membrane. Cyclophilin D, located in the matrix, facilitates MPT, probably through enhancing conformational change of inner membrane proteins. Recent studies in cyclophilin D-deficient animals show that this molecule is important for MPT (12) (13) (14) and that these mice are resistant to cell death caused by ischemic injury (12, 13) . However, MOMP and apoptosis induced by several proapoptotic agents remained intact, indicating that a cyclophilin D-independent mechanism (presumably MPT-independent) can also operate in apoptotic death.
This second major mechanism of MOMP involves the Bcl-2 family of proteins. These proteins share 1 or more Bcl-2 homology (BH) domains and control MOMP, mostly at the mitochondrial outer membrane. The proapoptotic multidomain proteins Bax and Bak (containing BH-1, -2, and -3) probably mediate MOMP, as these can permeabilize vesicles, are composed of mitochondrial lipids (15, 16) , and are required for MOMP to occur during apoptosis (17) . Bax and/or Bak can be activated by other Bcl-2 family proteins, the BH3-only proteins (which share BH3). Some of the proteins, notably Bid and Bim, can activate Bax (and probably Bak) directly, causing MOMP (16) . Antiapop-totic Bcl-2 family proteins (including Bcl-2, Bcl-x L , Mcl-1, and others) sequester the BH3-only proteins and probably the activated multidomain proteins, preventing MOMP. Other BH3-only proteins can antagonize the antiapoptotic proteins, thus sensitizing cells for death. These sensitizing or "derepressor" BH3-only proteins include Puma, Noxa, and Bad, among others (16, 18, 19) . Peptides and drugs that mimic the BH3-only proteins therefore have promise as agents that can cause MOMP and apoptosis, or sensitize cells for death (20) .
The caveats: apoptosis inhibition without cell death inhibition One major problem concerning the development of cell death inhibitors is the definition of cell death and hence the experimental
Figure 1
Checkpoints for apoptosis in the mitochondrial pathway. Most mammalian cell death proceeds via the mitochondrial pathway, as illustrated. Stimuli for the induction of apoptosis predominantly act by engaging proapoptotic members of the Bcl-2 family, which work to cause MOMP, and this is countered by the antiapoptotic Bcl-2 family members. Other cell death stimuli can cause MOMP by the induction of a mitochondrial permeability transition. In either case, release of proteins from the intermembrane space triggers the activation of caspases via the formation of an Apaf-1 apoptosome, which recruits and activates caspase-9. This, in turn, cleaves and activates the executioner caspases. The activation of caspase-3, -7, and -9 is antagonized by XIAP, which in turn can be inhibited by Smac, Omi, and other proteins released upon MOMP. Not shown here are other pathways of caspase activation and apoptosis, including the death receptor pathway, and those resulting in activation of caspase-1 and -2 (see text). ANT, adenosine nuclear transporter; VDAC, voltage-dependent anion channel; IMS, intermembrane space; ∆Ψm, mitochondrial transmembrane potential.
verification of cell death inhibition. It has long been assumed that two decisive events in cellular destruction are apoptotic chromatin condensation and the fragmentation of nuclear DNA detectable with the TUNEL technique. In many instances, the suppression of these nuclear signs of apoptosis has been interpreted as inhibition of cell death. However, inhibition of some signal-transducing events required for apoptotic DNA degradation frequently does not prevent cell death. Thus many studies involving, for instance, caspase inhibitors are flawed when they claim that caspase inhibition prevents cell death without clear demonstration of cellular survival. For example, one of the major DNA-degrading enzymes, caspase-activated DNase (CAD), strictly relies on caspase activation yet is not required for cell (49) A cell-permeable peptide containing the BH4 domain of Bcl-xL inhibits x-ray-induced apoptosis (50) in the small intestine of mice and partially suppresses anti-CD95-induced fulminant hepatitis. Transgenic expression of Bcl-2 or liposome-mediated delivery of the Bcl-2 gene protects against brain ischemia.
(51) Cardiomyocyte-specific transgenic expression of Bcl-2 reduces ischemia/reperfusion (52, 53) injury in the heart and mitigates a mouse model of chronic cardiomyopathy. Other proteins A variety of agents including cyclosporin A (the prototypic inhibitor of the permeability transition pore) (4) and inhibitors of mitochondrion-specific ion channels (such as diazoxide, an inhibitor of the MitoKATP channel, and diltiazem, an inhibitor of Na + Ca 2+ exchange) inhibit MOMP and exert neuro-and cardioprotective effects in mouse models. However, the specificity of these agents has not been validated genetically. The Omi/HtrA2-specific inhibitor ucf-101 inhibits the nephrotoxic, proapoptotic effect of cisplatin in mice.
Proteases
(63) Ucf-101 reduces infarct size after myocardial ischemia in mice.
(64)
Nonproteolytic death effectors

AIF
Neutralization of AIF can rescue neurons from cell death induced by DNA damage or excitotoxins.
(65) Harlequin mice, which bear a hypomorphic AIF mutation, have reduced ischemia/reperfusion damage of the brain.
Death receptors and their ligands
TNF-α
Neutralizing antibodies or soluble receptors are in clinical use for the treatment of rheumatoid arthritis and Crohn disease. See Table 2  CD95L Antibodies specific for CD95L promote regeneration and functional recovery after spinal cord injury in mice.
(66) Simultaneous, antibody-mediated neutralization of CD95L and TNF-α reduces infarct volume (67) and mortality in a mouse model of stroke. Mice lacking CD95L are resistant against neonatal hypoxic-ischemic brain injury (68, 69 ) and recover locomotor function more rapidly after spinal injury. DISC Suramin, which inhibits DISC-mediated caspase-8 activation, inhibits apoptotic liver damage (70) induced by CD95 stimulation and endotoxic shock-mediated TNF-α in mice.
Nuclear factors p53
An inhibitor of the transactivation function of p53, cyclic pifithrin-α (71) is radioprotective in mice, mimicking the effects of the p53 knockout. PARP PARP inhibitors and PARP-1 knockout reduce brain damage induced by stroke or MPTP in mice. 
death, as demonstrated by knockout studies (21) . So when CAD is inhibited (which often results in abolition of TUNEL staining), this may indicate that a given compound has achieved caspase inactivation, yet it does not demonstrate that the cell will actually survive. If cell death is evaluated by other techniques - by measurement of MOMP, by assessment of the long-term survival, or by functional assays - then caspase inhibition is often without any effect.
In the context of caspase inhibitors, cells often do not die by apoptosis but succumb to a delayed cell death (7, 8) that can have an apoptosis-like morphology (with peripheral chromatin condensation yet without karyorrhexis) (22) or manifest as autophagic cell death (with accumulation of autophagic vacuoles) (23) or necrotic death (with swelling of cytoplasmic organelles) (24) . Such "caspaseindependent cell death" is nevertheless under the same regulatory mechanisms upstream of MOMP that control apoptosis (7) .
Inhibition of MOMP may have a wider range of cytoprotective actions than inhibition of caspases (4) . Accordingly, the antiapoptotic proteins of the Bcl-2 family (which prevent MOMP) have a strong cytoprotective action, even in systems in which caspases play no role in cell death induction (25) . However, inhibition of MOMP is not a panacea against cell death. Thus, in conditions in which caspase activation is enforced through the ligation of death receptors or, for instance, by inhibitors of XIAP, cell death can occur without signs of MOMP, and genetic interventions on MOMP-regulatory proteins (such as overexpression of Bcl-2 or knockout of Bax and Bak) may not affect apoptotic cell death. Reportedly, successful MOMP inhibition can also cause a shift from apoptotic to autophagic cell death (26) .
Inhibition of cell death at the preclinical and clinical levels
The death of postmitotic cells in the CNS and myocardium, be it the result of an acute or a chronic degenerative process, is a pathogenic event. Similarly, septic shock, ischemia, and intoxication can cause massive apoptosis in multiple organs. Infections can cause an elevated apoptotic turnover of specific cell types, for instance, lymphocytes in AIDS or gastric mucosa cells in Helicobacter pylori infection. These diseases are therefore candidates for therapeutic cell death suppression.
A cornucopia of putative drugs and targets for cytoprotection are being explored at the preclinical and clinical levels (Tables 1  and 2 ). MOMP inhibitors have attracted interest, with encouraging results in animal models. Similarly, a variety of protease inhibitors are being designed to prevent cell death. Among this class of agents, caspase inhibitors have been extensively explored. This exploration has been driven by the often-erroneous belief that caspases would generally dictate the "point of no return" of cell death. Although some preclinical results are promising, many of the specific caspase inhibitors (such as zVAD-fmk and zDEVD-fmk) can actually inhibit calpains and cathepsins (27, 28) . Calpains and cathepsin can also be involved in pathogenic cell death, as indicated by pharmacological studies in rodents and genetic validation in mice (Table 2) . Genetic methods to inhibit caspases, for instance by overexpressing the baculovirus protein p35, have not validated the role of caspases in cell death, for instance in kainate-induced neurotoxicity (29) . Moreover, a proof-of-principle experiment illustrating that the conditional or tissue-specific knockout of 1 or several caspase genes can confer true cytoprotection is still elusive. In this sense, it is not surprising that clinical studies of caspase inhibitors assess the treatment of inflammatory diseases such as hepatitis C, in which the inhibition of inflammatory caspases (caspase-1 and perhaps caspase-4 and -5) may be the therapeutic goal.
Other strategies of cytoprotection target death-inducing molecules such as TNF-α and CD95L, the proapoptotic transcription factor p53 (which is activated by genotoxic stress as well as by some kinds of metabolic stress), poly(ADP-ribose) polymerase (PARP) (which is activated by DNA damage and hypoxia), or a variety of stress kinases (such as JNK3 or the mixed-lineage kinases [MLKs]) (Tables 1 and 2 ). Antioxidants may also blunt acute and unwarranted cell death. Some antiapoptotic compounds have been FDA approved ( Table 2 ). This applies in particular to agents targeting TNF-α, used to treat rheumatoid arthritis and Crohn disease. Whether such agents act as true cell death blockers or through their antiinflammatory effects, however, is an open question.
Cell damage sensors as targets for cell death induction
Damage to a variety of cellular organelles can lead to apoptosis. It is conceivable that each organelle possesses sensors that detect specific alterations, locally activate signal transduction pathways, emit signals that ensure interorganellar cross-talk, and ultimately stimulate the common apoptotic pathway, presumably by activating the central executioner (30) .
Proteins that belong to the family of PI3K-like kinases sense the DNA damage response. This family includes ATM (ataxia telangiectasia mutated), ATR (ATM- and Rad-3-related), and DNAdependent protein kinase (DNA-PK). In human cells, this directly or indirectly results in the phosphorylation of p53, modulating the DNA-binding activity of p53 and enhancing its stability. The tumor suppressor protein p53 mediates part of the response of mammalian cells to DNA damage, either by stimulating DNA repair or, beyond a certain threshold of DNA damage, by initiating apoptosis. Transcription factor p53 transactivates a number of proapoptotic proteins from the Bcl-2 family (in particular Bax, Bid, Puma, and Noxa), which induce MOMP and release apoptogenic factors from the mitochondrial intermembrane space. p53 may also induce apoptosis in a transcription-independent manner, by direct physical interactions with members of the Bcl-2 family (31-33). Reactivation of mutated p53 hence is one of the strategies used to kill tumor cells, in which p53 is frequently mutated or inactivated. Thus a reactivation may be mediated by p53-expressing adenovirus or by small molecules that reestablish the normal conformation of mutated p53.
While DNA damage often induces p53-dependent apoptosis (which implies that p53-mutated tumor cells do not respond to genotoxic agents), there are a variety of techniques to induce apoptosis by damaging organelles other than the nucleus, a priori in a p53-independent fashion. One possibility is to use agents that cause lysosomal membrane permeabilization, leading to the cytosolic release of cathepsins B and D, which are normally secluded in the lumen of lysosomes (34, 35) . Cathepsins then trigger an apoptotic response that involves MOMP, followed by caspase activation (36) . Alternatively, one can attempt to trigger MOMP by agents directly acting on mitochondria, again bypassing p53 dependency (4). Finally, it is possible to trigger apoptosis via the ER, by inducing the unfolded protein response or by stimulating lethal Ca 2+ fluxes (30) .
Although there are many ways to stimulate apoptotic responses by compounds inducing organelle-specific damage, thus far no agent specifically acting on cytoplasmic organelles has made it into clinical trials for the treatment of neoplasia. However, ligands of so-called death receptors (such as CD95/Fas, TNFR, and the 2 receptors of TRAIL) are being evaluated as potential anticancer agents that could bypass the resistance against conventional chemotherapy (Table 3) .
Cell death induction: the problem of specificity
It is easy to trigger apoptosis in most vertebrate cells; the problem is to do this in such a way that only those cells we wish to target die. This is the basis for most cancer therapies but also applies to any situation in which a particular cell population is responsible for disease. For example, selective elimination of a subpopulation of immune cells can form the basis of therapy for inflammatory or autoimmune disease, while specific death of hyperplastic fibroblasts can impact connective tissue diseases. Similarly, we can protect cells from death, but again, specificity is required to ensure that such protection does not promote undesirable cell survival, leading to hyperaccumulation or cancer.
One key to specificity may come with a deeper understanding of why a disease-causing cell does not undergo cell death through normal homeostatic mechanisms. For example, it is well established that signals to enter the cell cycle simultaneously sensitize cells for apoptosis, such that tissue expansion depends on availability of exogenous survival factors (37) . A cell that bypasses the homeostatic apoptotic mechanisms (e.g., through mutation or overexpression of cell death regulators) will, in theory, only have interrupted one physiologically relevant pathway of apoptosis, while leaving other pathways intact and with heightened sensitivity. This is likely the reason why agents that broadly target cells for DNA damage, microtubule breakdown, protease dysfunction, or defects in metabolism can have relatively specific effects on cancer cells, forming the basis of many established approaches to cancer therapy. By understanding and targeting such pathways specifically, we can improve therapies with fewer side effects.
Therapeutic cell death induction at the preclinical and clinical levels
Most cytotoxic agents used in anticancer chemotherapy induce apoptosis, although very few actually directly target the apoptotic (Table 3) . Oblimersen (G3139, Genasense) is an antisense oligonucleotide that targets human bcl-2 mRNA. This compound, which has been tested in clinical trials with encouraging results, constitutes the prototype of a new therapeutic concept targeting antiapoptotic molecules. Small molecules targeting Bcl-2 and its relatives are also being developed (20) . p53-expressing adenoviruses as well as an adenovirus designed to replicate in p53-deficient tumor cells (ONYX-015) are also being clinically tested for cancer treatment. TNF-α has been approved for isolated limb perfusion, in which the recombinant protein is injected into an artery of a limb affected by nonresectable melanoma. TRAIL or agonistic antibodies targeting TRAIL-R1 or TRAIL-R2 have entered the early stage of clinical evaluation. A specific PARP inhibitor has also been tested for chemosensitization of brain cancers. More importantly, an inhibitor of the proteasome bortezomib (Velcade) has been approved for chemotherapy of multiple myeloma and is under evaluation as a single agent or in combination chemotherapy for the treatment of hematopoietic and solid cancers (Table 3) .
However, the true revolution in cancer therapy concerns the therapeutic use of kinase inhibitors targeting protein kinases whose activity is required for cancer cell proliferation and/or survival ( Table 3) . As an example, one of the prototypic kinase inhibitors, imatinib mesylate (Gleevec), can eradicate BCR/ABL-positive leukemia cells, presumably through the induction of apoptotic (38) or nonapoptotic, caspase-independent (39) cell death. The FDA has approved several other specific inhibitors of survival kinases recently, and dozens are currently under preclinical development.
Conclusions and perspectives: this series
The current Review Series contains 9 Reviews of areas in cell death research that hold promise for the development of therapeutics.
The Review by Amaravadi and Thompson (40) considers this problem from the perspective of the signaling pathways, in particular the kinases, that control cell survival. This includes not only regulation of apoptosis, per se, but also the signals that control metabolic demand and, in turn, control life and death. Other survival signals, notably those controlled by NF-κB, are reviewed by Luo et al. (41) and considered with respect to cancer therapy. In addition, cellular survival can be preserved by the functions of members of the heat shock protein family, an active area of research that is reviewed by Beere (42) . In all of these cases, important targets have been identified, and agents to modulate them are in different stages of development and testing for use in human disease.
As outlined above, the mitochondria sit at the center of a major pathway for cell death controlled by multiple inputs, and this can result in apoptosis or other forms of cell death. Bouchier-Hayes and colleagues (43) consider the mitochondria as a target for pharmacological intervention, especially with respect to control of the Bcl-2 family proteins. Strategies for elaborating specific apoptosis modulators that mimic Bcl-2 family proteins or act on such proteins are discussed by Letai (44) . Another organelle that appears to control cell life and death is the ER, which coordinates complex signaling events around calcium storage and the unfolded protein response as well as other forms of ER stress. Xu et al. (45) consider the signal transduction pathways that center on the ER with respect to cell death and its control.
The regulation of caspase activation is, of course, highly relevant to the manipulation of apoptosis, and this subject is reviewed by Lavrik and colleagues (46) . Similarly, the IAPs have for some time been thought of predominantly as caspase inhibitors. Recent discoveries have shown that these also play roles distinct from the control of caspases, acting as ubiquitin ligases for other proteins, passenger molecules, and signal transduction proteins. Wright and Duckett (47) consider IAPs as pharmacological targets and how these affect various outcomes in the cell and organism.
Finally, the process of autophagy, distinct from that of apoptosis, accompanies cell death in many cases, and it is possible that this "selfeating" may result in death, or, alternatively, may represent a mechanism for cell survival. Levine and Yuan (48) discuss this process and consider pharmacological approaches to its manipulation.
Many drug targets elucidated in studies of cell death have led to approved pharmacological agents that are currently in use, while many more are in clinical trial. These are promising, of course, but we are only beginning to understand these processes and their potential for clinical benefit. The application of our understanding is now in sight, but the potential extends beyond our vision.
